The FDA has granted priority review status to Regeneron Pharmaceuticals’ (NASDAQ: [[ticker:REGN]]) experimental treatment for age-related macular degeneration (AMD), according to a press release. The drug, called VEGF Trap-Eye, is specifically designed to treat the neovascular form of the disease, which is commonly known as “wet AMD.” The target date for the FDA to hand over its verdict to the Tarrytown, NY-based company is August 20.
Author: Arlene Weintraub
Arlene is an award-winning journalist specializing in life sciences and technology. She was previously a senior health writer based out of the New York City headquarters of BusinessWeek, where she wrote hundreds of articles that explored both the science and business of health. Her freelance pieces have been published in USA Today, US News & World Report, Technology Review, and other media outlets. Arlene has won awards from the New York Press Club, the Association of Health Care Journalists, the Foundation for Biomedical Research, and the American Society of Business Publication Editors. Her book about the anti-aging industry, Selling the Fountain of Youth, was published by Basic Books in September 2010.
View all posts by Arlene Weintraub
